Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)

Ani Pharmaceuticals (ANIP) has disclosed Restructuring Costs for 2 consecutive years, with $2000.0 as the latest value for Q2 2023.

  • Quarterly Restructuring Costs fell 99.92% to $2000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Mar 2024, down 99.97% year-over-year, with the annual reading at $1.1 million for FY2023, 80.07% down from the prior year.
  • Restructuring Costs hit $2000.0 in Q2 2023 for Ani Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $2.6 million in Q2 2022 to a low of $2000.0 in Q2 2023.